News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,702 Results
Type
Article (40903)
Company Profile (267)
Press Release (680522)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204668)
Career Advice (2023)
Deals (35535)
Drug Delivery (110)
Drug Development (81386)
Employer Resources (173)
FDA (16410)
Job Trends (14944)
News (346390)
Policy (32725)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2567)
Accelerated approval (32)
Adcomms (24)
Allergies (142)
Alliances (49577)
ALS (169)
Alzheimer's disease (1667)
Antibody-drug conjugate (ADC) (310)
Approvals (16679)
Artificial intelligence (514)
Autoimmune disease (153)
Automation (39)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (189)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (56)
Breast cancer (638)
Cancer (4799)
Cardiovascular disease (398)
Career advice (1708)
Career pathing (36)
CAR-T (282)
CDC (44)
Celiac Disease (2)
Cell therapy (743)
Cervical cancer (36)
Clinical research (69564)
Collaboration (1700)
Company closure (4)
Compensation (1157)
Complete response letters (54)
COVID-19 (2710)
CRISPR (88)
C-suite (841)
Cystic fibrosis (143)
Data (6217)
Decentralized trials (2)
Denatured (25)
Depression (131)
Diabetes (500)
Diagnostics (6687)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (253)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (231)
Earnings (90166)
Editorial (57)
Employer branding (21)
Employer resources (152)
Events (117272)
Executive appointments (971)
FDA (19521)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1466)
Gene editing (194)
Generative AI (43)
Gene therapy (594)
GLP-1 (966)
Government (4659)
Grass and pollen (6)
Guidances (383)
Healthcare (18872)
HIV (58)
Huntington's disease (44)
IgA nephropathy (83)
Immunology and inflammation (249)
Immuno-oncology (57)
Indications (110)
Infectious disease (2978)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (248)
Interviews (315)
IPO (16644)
IRA (50)
Job creations (3642)
Job search strategy (1428)
JPM (57)
Kidney cancer (16)
Labor market (85)
Layoffs (546)
Leadership (31)
Legal (7949)
Liver cancer (91)
Longevity (14)
Lung cancer (646)
Lymphoma (376)
Machine learning (42)
Management (59)
Manufacturing (792)
MASH (163)
Medical device (13768)
Medtech (13821)
Mergers & acquisitions (19961)
Metabolic disorders (1266)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (314)
Neuropsychiatric disorders (88)
Neuroscience (2892)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4514)
Now hiring (67)
Obesity (594)
Opinion (257)
Ovarian cancer (166)
Pain (198)
Pancreatic cancer (226)
Parkinson's disease (279)
Partnered (33)
Patents (495)
Patient recruitment (489)
Peanut (56)
People (58864)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21684)
Phase 2 (30615)
Phase 3 (22810)
Pipeline (5270)
Policy (281)
Postmarket research (2564)
Preclinical (9196)
Press Release (64)
Prostate cancer (237)
Psychedelics (48)
Radiopharmaceuticals (279)
Rare diseases (831)
Real estate (5955)
Recruiting (70)
Regulatory (24478)
Reports (52)
Research institute (2387)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (77)
Schizophrenia (148)
Series A (238)
Series B (190)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3614)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (54)
Vaccines (1002)
Venture capital (88)
Weight loss (380)
Women's health (91)
Worklife (18)
Date
Today (104)
Last 7 days (611)
Last 30 days (2113)
Last 365 days (29915)
2026 (3417)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55711)
2020 (54083)
2019 (46539)
2018 (35018)
2017 (32113)
2016 (31485)
2015 (37554)
2014 (31319)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (309)
Arkansas (13)
Asia (39230)
Australia (6409)
California (11281)
Canada (3284)
China (1099)
Colorado (477)
Connecticut (475)
Delaware (336)
Europe (84510)
Florida (1688)
Georgia (355)
Hawaii (3)
Idaho (61)
Illinois (859)
India (65)
Indiana (519)
Iowa (22)
Japan (430)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1381)
Massachusetts (8078)
Michigan (324)
Minnesota (628)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (2999)
New Mexico (28)
New York (2972)
North Carolina (1449)
North Dakota (8)
Northern California (5513)
Ohio (333)
Oklahoma (21)
Oregon (41)
Pennsylvania (2275)
Puerto Rico (24)
Rhode Island (48)
South America (1108)
South Carolina (66)
South Dakota (1)
Southern California (4389)
Tennessee (174)
Texas (1740)
United States (39974)
Utah (334)
Vermont (1)
Virginia (260)
Washington D.C. (81)
Washington State (918)
West Virginia (4)
Wisconsin (108)
Wyoming (2)
721,702 Results for "beyondspring inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
February 9, 2026
·
1 min read
Press Releases
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
·
12 min read
Press Releases
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
December 12, 2025
·
3 min read
Press Releases
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
December 11, 2025
·
5 min read
Press Releases
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
May 28, 2025
·
2 min read
Press Releases
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
·
8 min read
Business
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today provided a business update and reported results for the year ended December 31, 2023.
April 29, 2024
·
10 min read
Press Releases
BeyondSpring Files 2024 Annual Report on Form 10-K
March 28, 2025
·
2 min read
Business
BeyondSpring Files 2023 Annual Report on Form 20-F
BeyondSpring Inc. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission on April 29, 2024.
April 29, 2024
·
2 min read
Pharm Country
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”) today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET.
May 3, 2024
·
5 min read
1 of 72,171
Next
